ASCO 2025 Press Releases Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-altered mCSPC ImmunityBio Receives FDA Expanded Access Authorization for ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

AUA 2025 Upper Tract Urothelial Carcinoma AUA 2025: Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High Risk Upper Tract Urothelial Carcinoma AUA 2025: Long-Term ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Tumor suppressor genes play a critical role in prostate cancer progression, with alterations in PTEN, TP53, and RB1 representing some of the most clinically significant genomic events. These ...

Matthew Cooperberg speaks with Martin Gleave about GUNS, a neoadjuvant adaptive umbrella trial for men with high-volume, high-grade prostate cancer. Now at 280 patients enrolled, GUNS sequences needle ...

Peyronie's disease (PD) is an acquired fibrotic condition of the tunica albuginea that is characterized by penile curvature, deformity, pain, and impaired sexual function. PD is prevalent among all ...

Creating real-time access to evidence-based findings from anywhere in the world, coverage written by clinicians for urology, medical oncology, and radiation oncology conferences.

(UroToday.com) The 2026 SESAUA annual meeting featured a bladder cancer session and presentation by Dr. Veerain Gupta discussing patient time toxicity from management options for non-muscle invasive ...

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Niven Mehra discussing how to optimize ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Martin Gleave discussing how to optimize ...